Screener
Eikon Therapeutics, Inc. EIKN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | (15,065) | (9,384) |
| Operating lease liabilities | (2,488) | 16,023 |
| Other liabilities | — | (311) |
| Net cash used in operating activities | (89,801) | (54,521) |
| Investing Activities | ||
| Purchase of property and equipment | (262) | (22,358) |
| Purchase of marketable securities | (306,955) | (252,496) |
| Proceeds from maturities of marketable securities | 104,000 | 61,000 |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s operating cash flow?
- Eikon Therapeutics, Inc. (EIKN) reported operating cash flow of -$89.8M in Q1 2026.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Eikon Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude